Chen Siyuan, GSK's vice president of China and head of breathing operations, will leave

another long-rumoured news hammer!On November 18, GlaxoSmithKline China announced that Chen Siyuan, GSK's vice president of China and vice president of its breathing and HIV business, had decided to leave his post to pursue external development opportunities, with the last working day of the month.
, Sun Lei, the current head of the hepatitis business, was appointed head of the anti-infection business unit to take over the HIV business, effective December 1.
, the new head of the respiratory business has not been identified, the breathing business is temporarily led by GSK China General Manager Fabio Landazabal, sales work is temporarily under the responsibility of the current specialty medicine and CNS business unit head Chenxuan.Since the departure of Wang Wei, head of GSK's China respiratory operations, to join Lilly in April last year, the respiratory business has under made a number of personnel and restructuring changes.
First, in April this year, the then head of the respiratory business, Gao Wei, left office to breathe new and old products separately, with Chen Siyuan and Zhu Ning in charge of the Innovative Products Business Unit (CNS, HIV) and the Classic Products Business Unit (-Hepatitis).
May, Zhu Ning left his post to join Lilly China's Cross Bio-Chemical Products Division as Vice President of specialty pharmaceutical products division, and GSK Classic Products business unit was associated to Chen Siyuan as the Respiratory and HIV business unit.Today, the news of Chen Siyuan's departure was officially confirmed, according to Dami understand, will go to another multinational pharmaceutical company important positions. (Medical representative)